(MENAFN- GlobeNewsWire - Nasdaq) Cell counting market growth is projected to be high in the forthcoming years.
Fort Collins, Colorado, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Cell Counting Market size was valued at USD 9.1 Billion in 2023 and is expected to have a market size of USD 17.2 Billion by 2032 with a CAGR of 7.5%.
The cell counting market has witnessed significant growth in recent years, driven by advancements in cell biology research, an increasing prevalence of chronic diseases, and the rising demand for personalized medicine. Cell counting is crucial in various applications, including cancer research, drug discovery, and regenerative medicine. Technological advancements have been pivotal in shaping the cell counting market landscape. Automated cell counting systems with sophisticated imaging and analysis capabilities have gained prominence, offering higher accuracy and reproducibility than manual counting methods.
The increasing prevalence of chronic and infectious diseases is a significant driver fueling the demand and growth of the global cell counting market. As these diseases become more widespread, there is a huge need for advanced diagnostic and research tools to understand the underlying cellular mechanisms and develop effective treatments. For infectious diseases, accurate cell counting is crucial for monitoring immune responses and assessing the efficacy of antiviral or antibacterial treatments. Besides, the need for personalized medicine drives the demand for cell counting technologies for chronic diseases, such as cancer and autoimmune disorders. Researchers require precise cell counts to analyze patient samples, identify specific cellular abnormalities, and tailor treatment strategies based on individual profiles.
Integrating AI and Machine Learning in cell counting instruments presents growth avenues to prominent market players. Combining AI and machine learning has introduced a new level of superiority in cell counting instruments, expanding their capabilities beyond mere quantification. These intelligent systems can classify cell types, assess cell viability, and even detect anomalies or irregularities in cellular structures.
Request Sample Report:
The global cell counting market has been segmented into product, application, end-use, and region. Based on the product, the cell counting market is segmented into instruments, consumables & accessories. The instruments segment held the largest market share and accounted for a revenue share of 56.7% in 2023. The instrument segment is further categorized into spectrophotometers, flow cytometers, hemocytometers, automated cell counters, microscopes, and others.
Buy This Research Report:
Cell Counting Market Report Highlights:
The global cell counting market growth is anticipated at a CAGR of 7.5% by 2032.
The growing focus on personalized medicine drives demand and growth in the global cell counting market. Personalized medicine aims to tailor treatments to individual patients based on their genetic makeup, lifestyle, and specific disease characteristics.
North America held the largest market share and accounted for a revenue share of 38.2% in 2023. This can be attributed to a sophisticated research infrastructure, substantial healthcare investments, and a thriving pharmaceutical sector. The region's proactive adoption of cutting-edge technologies with a strong emphasis on precision medicine propels the demand for advanced cell counting instruments.
Some prominent players in the cell counting market report include Thermo Fisher Scientific Inc., Merck & Co., Inc., Agilent Technologies, PerkinElmer, Inc. (Revvity), BD (Becton, Dickinson and Company), Danaher, GE Healthcare, Bio-Rad Laboratories, DeNovix Inc., and Corning Inc..
Industry Trends and Insights:
- In 2023, Chinese scientists developed an AI-based approach for cell counting to minimize errors in the traditional approach. For this purpose, scientists have developed a deep-learning network called the Spatial-Based Super-Resolution Reconstruction Network. The automated methodology predicts cell counting and cell distribution with high precision.
- According to Francis Crick Institute and Moris Laboratory researchers, cell consistency has been crucial to understanding early embryonic development. To understand the mechanism behind human development, the Moris Laboratory has been following the gastrulation process, which is an early step in embryonic development.
Looking Exclusively For Region/Country Specific Report?
Ask For Discount
Cell Counting Market Segmentation:
By Product: Instruments (Spectrophotometers, Flow Cytometers, Hemocytometers, Automated Cell Counters, Microscopes, Others), and Consumables & Accessories (Reagents, Microplates, Others).
By Application: Complete Blood Count, Stem Cell Research, Cell-based Therapeutics, Bioprocessing, Toxicology, and Others.
By End-use: Hospitals & Diagnostic Laboratories, Research & Academic Institutes, Pharmaceutical & Biotechnology Companies, and Others.
By Region: North America, Latin America, Europe, Asia Pacific, the Middle East and Africa.
About DataHorizzon Research:
DataHorizzon is a market research and advisory company that assists organizations across the globe in formulating growth strategies for changing business dynamics. Its offerings include consulting services across enterprises and business insights to make actionable decisions. DHR's comprehensive research methodology for predicting long-term and sustainable trends in the market facilitates complex decisions for organizations.
Follow Us: LinkedIn
Migraine Drugs Market 2023 to 2032
Infertility Treatment Market 2023 to 2032
Immunotherapy Drugs Market 2023 to 2032
Diabetes Injection Pens Market 2023 to 2032
Dexamethasone Market 2023 to 2032
CONTACT: Mail: ...
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.